Astrana Health (NASDAQ:ASTH) Issues Quarterly Earnings Results, Beats Estimates By $0.39 EPS

Astrana Health (NASDAQ:ASTH) released its earnings results on Monday. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.39, FiscalAI reports. Astrana Health had a net margin of 0.33% and a return on equity of 1.26%. The business had revenue of $950.53 million during the quarter, compared to the consensus estimate of $930.46 million. During the same quarter last year, the firm earned ($0.15) earnings per share. The firm’s revenue for the quarter was up 42.9% compared to the same quarter last year.

Here are the key takeaways from Astrana Health’s conference call:

• Astrana closed 2025 with record results — $3.2B revenue, $205.4M adjusted EBITDA, and $104.5M free cash flow; Q4 revenue was $950.5M (up 43%) and adjusted EBITDA $52.5M (up 50%).
• 2026 guidance is for $3.8B–$4.1B revenue, $250M–$280M adjusted EBITDA, and $105M–$132.5M free cash flow, but management framed this as deliberately conservative and sensitive to Medicaid/exchange disenrollment and medical cost trends.
• The Prospect Health acquisition integration is reported as on track with >97% PCP retention and management now expects to realize the high end of the previously announced $12M–$15M annualized synergies.
• The company disclosed a material weakness in internal controls over acquisition/purchase accounting and will file a Form 12b‑25 with the 10‑K delayed into the 15‑day extension period, with remediation underway.
• Management highlighted its technology and AI-driven Astrana Care Enablement platform as a driver of operating leverage — G&A fell to 6.8% of revenue and automation/AI are expected to further improve margins and speed expansion into new markets.

Astrana Health Trading Up 29.5%

ASTH stock opened at $26.32 on Tuesday. Astrana Health has a one year low of $18.08 and a one year high of $34.80. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of 138.53, a price-to-earnings-growth ratio of 0.61 and a beta of 0.91. The company has a fifty day moving average price of $23.56 and a two-hundred day moving average price of $26.28. The company has a debt-to-equity ratio of 1.27, a current ratio of 1.40 and a quick ratio of 1.40.

Institutional Trading of Astrana Health

Several hedge funds and other institutional investors have recently modified their holdings of ASTH. Tower Research Capital LLC TRC raised its holdings in Astrana Health by 323.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $115,000 after acquiring an additional 3,517 shares during the period. State of Wyoming acquired a new position in shares of Astrana Health in the second quarter valued at approximately $132,000. Los Angeles Capital Management LLC bought a new position in shares of Astrana Health during the fourth quarter worth approximately $228,000. WINTON GROUP Ltd bought a new position in shares of Astrana Health during the second quarter worth approximately $233,000. Finally, Brevan Howard Capital Management LP acquired a new stake in Astrana Health during the 2nd quarter worth approximately $277,000. Institutional investors own 52.77% of the company’s stock.

Key Astrana Health News

Here are the key news stories impacting Astrana Health this week:

• Positive Sentiment: Q4 results beat consensus — Astrana reported $0.54 EPS (vs. $0.15 est.) and $950.5M revenue (vs. $930.5M est.), with revenue up ~43% year-over-year, which is the primary catalyst for the stock lift today. Astrana Health, Inc. Reports Fourth Quarter and Year End 2025 Results
• Neutral Sentiment: FY-2026 and Q1-2026 revenue guidance issued roughly in line with Street expectations (FY: ~$3.8B–$4.1B vs. ~$3.9B consensus; Q1: ~$900M–$1.0B vs. ~$927.8M consensus), but EPS guidance was not provided in the update, leaving margin/earnings visibility limited. Press Release / Guidance Details
• Neutral Sentiment: Management commentary is available in the Q4 earnings call transcript for investors who want detail on drivers (volume growth, margins, guidance assumptions). Review the transcript for color on growth sustainability and cost outlook. Astrana Health, Inc. (ASTH) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Short-interest data posted is anomalous (shows 0 shares / NaN change), so there’s no clear short-pressure signal from the published short-interest snapshot; treat that data as unreliable until corrected.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. TD Cowen decreased their price objective on Astrana Health from $40.00 to $35.00 and set a “buy” rating for the company in a report on Monday, November 10th. Barclays reduced their price target on Astrana Health from $36.00 to $26.00 and set an “equal weight” rating for the company in a research report on Monday, November 24th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrana Health in a research report on Tuesday, November 25th. Needham & Company LLC began coverage on Astrana Health in a research note on Friday, December 12th. They set a “buy” rating and a $28.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Astrana Health in a research note on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Astrana Health currently has an average rating of “Hold” and an average price target of $37.29.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.